Tag: Kim Bellard

Searching For The Next Search

Dec 28, 2022

By KIM BELLARD

I didn’t write about ChatGPT when it was first introduced a month ago because, well, it seemed like everyone else was. I didn’t play with it to see what it could do. I didn’t want it to write any poems. I didn’t have any AP tests I wanted it to pass. And, for all you know, I’m not using it to write this. But when The New York Times reports that Google sees ChatGPT as a “Code Red” for its search business, that got my attention.

A few months ago I wrote about how Google saw TikTok as an existential threat to its business, estimating that 40% of young people used it for searches. It was a different kind of search, mind you, with video results instead of links, but that’s what made it scary – because it didn’t just incrementally improve “traditional” search, as Google had done to Lycos or Altavista, it potentially changed what “search” was.

TikTok may well still do that (although it is facing existential issues of its own), but ChatGPT could pose an even greater threat. Why get a bunch of search results that you still have to investigate when you could just ask ChatGPT to tell you exactly what you want to know?

Look, I like Google as much as anyone, but the prospect that its massive dominance of the search engine market could, in the near future, suddenly come to an end gives me hope for healthcare. If Google isn’t safe in search, no company is safe in any industry, healthcare included.

Netflix for Drugs?

Dec 21, 2022

By KIM BELLARD

A relative — obviously overestimating my healthcare expertise — asked my thoughts on The New York Times article Can a Federally Funded ‘Netflix Model’ Fix the Broken Market for Antibiotics? I had previously skimmed the article and was vaguely aware of the Pasteur Act that it discusses, but, honestly, my immediate reaction to the article was, gosh, that may not be a great analogy: do people realize what a tough year Netflix has had?

I have to admit that I tend to stay away from writing about Big Pharma and prescription drugs, mainly because, in a US healthcare system that seems to pride itself on being opaque, frustrating, and yet outrageously expensive, the prescription drug industry takes the cake. It’s too much of a mess.

But a “Netflix model” for drug development? Consider me intrigued.

It’s easy to understand why market forces might not do well with rare diseases that need an “orphan drug,” but the “subscription model” approach that the Pasteur Act seeks to address is something that most of us need: antibiotics. Antibiotic resistance has made many of our front-line antibiotics less effective, but discovering new antibiotics is a slow, expensive process, and many pharmaceutical companies are reluctant to take the risk. The Pasteur Act would essentially pay for their development in return for “free” use of subsequently invented drugs.

THCB Gang Episode 110, Thursday December 15

Dec 15, 2022

Joining Matthew Holt (@boltyboy) on #THCBGang on Thursday December 15 were patient safety expert and all around wit Michael Millenson (@mlmillenson); policy expert consultant/author Rosemarie Day (@Rosemarie_Day1); writer Kim Bellard (@kimbbellard), consumer expert Lygeia Riccardi (@Lygeia) radiologist Saurabh Jha (@RogueRad), and Olympic rower for 2 countries and all around dynamo Jennifer Goldsack, (@GoldsackJen). It was a full house and lots of fun, with a lot wrapped round the theme of protecting consumers (or not) online.

You can see the video below & if you’d rather listen than watch, the audio is preserved as a weekly podcast available on our iTunes & Spotify channels.

Give Kids a Healthy Itch

Dec 7, 2022

by KIM BELLARD

Someday I’ll probably write about Neuralink, but these days I don’t feel like giving Elon Musk any extra publicity. I also had the notion to take OpenAI’s newly announced ChatGPT down a rabbit hole about U.S. healthcare, just to see where it would go, but Mr. Musk has his fingerprints on that organization too. Then I saw something worth celebrating: Scratch has hit 100 million users worldwide.

What’s that? You’re not familiar with Scratch? Well, me neither, until last week. Now that I know a little about it, I kind of feel how I felt when I first discovered TikTok, found out about Roblox, or learned about Raspberry Pi. In all cases, there were big ecosystems aimed at young people, getting them to view tech-related things (e.g., gaming, coding, even building computers) as something natural, something fun, something easy to do, and those ecosystems were largely invisible to most adults.

I’m still waiting for the ecosystem that makes health like that for young people.

Scratch modestly describes itself as a “coding platform for children.”

THCB Gang Episode 108, Thursday December 1

Dec 1, 2022

Joining Matthew Holt (@boltyboy) on #THCBGang on Thursday November 17 were futurist Jeff Goldsmith; THCB regular writer and ponderer of odd juxtapositions Kim Bellard (@kimbbellard); patient safety expert and all around wit Michael Millenson (@mlmillenson); fierce patient activist Casey Quinlan (@MightyCasey); and Olympic rower for 2 countries and all around dynamo Jennifer Goldsack, (@GoldsackJen). This was quite the conversation!

You can see the video below & if you’d rather listen than watch, the audio is preserved as a weekly podcast available on our iTunes & Spotify channels.

Barcodes Are Us

Nov 29, 2022

BY KIM BELLARD

Usually I write about things where I see some unexpected parallel to healthcare, or something just amazed me, or outraged me (there are lots of things about healthcare like the latter). But sometimes I run across something that just delights me.

So when I inexplicably stumbled across DNA Barcoding Technology for High Throughput Cell-Nanoparticle Study, by Andy Tay, PhD, my first thought was, oh, nanoparticles, that’s always interesting, then it hit me: wait, DNA has barcodes?

How delightful.

THCB Gang Episode 106, Thursday November 10

Nov 10, 2022

After an early Fall hiatus, THCB Gang is back!! Joining Matthew Holt (@boltyboy) for #THCBGang on Thursday November 10 were medical historian Mike Magee (@drmikemagee); futurist Jeff Goldsmith; THCB regular writer and ponderer of odd juxtapositions Kim Bellard (@kimbbellard); and policy consultant/author Rosemarie Day (@Rosemarie_Day1). You can imagine that elections were on our collective minds.

You can see the video below & if you’d rather listen than watch, the audio is preserved as a weekly podcast available on our iTunes & Spotify channels.

And you thought Mastadons were extinct…

Nov 8, 2022

by KIM BELLARD

Until last week, for me, “mastodon” only meant the giant animal that went extinct several thousand years ago (I was, it appears, unaware of the heavy metal band Mastodon). Now, as the result of Elon Musk’s purchase of Twitter, many Twitter users are being forced to take a look at alternatives, such as the social networking site Mastodon.

It’s possible that we are about the witness the Myspace-ization of Twitter, brought down by competition, bad management, and bad product decisions. In my usual “there must be a pony in here somewhere” fashion, there may be some lessons in the Twitter saga that healthcare might want to pay attention to.

As most know by now, Mr. Musk has been a Twitter power user for many years, and a frequent critic. In March of this year he started discussions about purchasing it. In short order, he threw out a bold bid, was rejected then accepted by Twitter’s board, tried to get out of the deal, was sued by Twitter, and closed the deal late last month.

Then things got really rocky.

Mr. Musk tried to reassure squeamish advertisers, only to make them and others even more nervous when he retweeted some disinformation. After a spike in hate speech on the site, he promised that, as much as he was buying Twitter out of his love for free speech, Twitter “cannot become a free-for-all hellscape, where anything can be said with no consequences!” Then he shocked observers (and Twitter employees) by suddenly laying off half the workforce, including much of the content moderation staff. Some are now being asked back, being told they were laid off “by mistake.”

He then floated a balloon about charging $20 a month for Twitter’s blue verification, had a tweet argument with Stephen King about it, then went forward with a $7.99 plan, only to be punked by users illustrating the flaws. At this writing, the plan now appears to be on hold, at least until Tuesday’s mid-term elections.

Advertisers appear to be fleeing, or at least curtailing spending.

As The Wall Street Journal put it: “In Elon Musk’s first week at Twitter Inc., he flouted much of the advice management gurus have dished out for decades.” It’s no wonder many Twitter users are looking at Mastodon.

Rethinking Newer Events

Nov 1, 2022

BY KIM BELLARD

It’s a lot more fun to write about exciting new technologies, or companies in other industries that healthcare could learn from, than to pick on healthcare for its many, well-known shortcomings, but there was an article in JAMA Forum last week that I had to note and perhaps expand on: A New Category of “Never Events” – Ending Harmful Hospital Policies, by Dave A. Chokshi, MD, MSc and Adam L. Beckman, BS (he is also an MD/MBA student).

The concept of a “Never Event” is well known by this point. Coined some twenty years ago by Ken Kizer, MD of the National Quality Form (NQF) and soon widely adopted and expanded, it recognizes that healthcare sometimes has egregious errors that shouldn’t happen: the wrong foot is amputated, the wrong drug/dosage is given, surgical instruments are left inside a patient, and so on. Organizations like The Leapfrog Group exist largely to try to measure and compare hospitals on such patient safety issues.

Art Is in the Eye of the Computer

Oct 25, 2022

BY KIM BELLARD

It turns out that I’ve been writing about Generative AI without even realizing there was something called Generative AI, such as articles about the robot artist Ai-Da, the AI image creator DALL-E, or patent protection for AI inventors. Generative AI refers to AI that strives not just to process and synthesize data but to actually be creative. It’s starting to both become more widespread and to attract serious attention from investors.

James Currier of investment firm NFX sees “Generative Tech” as the next big thing: “If crypto hadn’t happened, we’d probably be calling THIS Web3.” He distinguishes Generative AI from Generative Tech as:

Some have called it “Generative AI,” but AI is only half of the equation. AI models are the enabling base layers of the stack. The top layers will be thousands of applications. Generative Tech is about what will actually touch us – what you can do with AI as a partner.

He predicts Generative Tech will generate “trillions of dollars of value.” I’m hoping that healthcare is paying attention.